Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
ATRA Atara Biotherapeutics, Inc. daily Stock Chart
ATRA [NASD]
Atara Biotherapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-6.09 Insider Own0.70% Shs Outstand56.05M Perf Week10.44%
Market Cap865.97M Forward P/E- EPS next Y-4.93 Insider Trans-0.39% Shs Float53.08M Perf Month17.89%
Income-292.50M PEG- EPS next Q-1.34 Inst Own- Short Float19.66% Perf Quarter3.07%
Sales- P/S- EPS this Y-31.60% Inst Trans15.83% Short Ratio15.05 Perf Half Y-30.00%
Book/sh5.80 P/B2.66 EPS next Y11.50% ROA-86.30% Target Price29.13 Perf Year-63.74%
Cash/sh5.05 P/C3.06 EPS next 5Y- ROE-99.70% 52W Range10.38 - 43.38 Perf YTD-55.53%
Dividend- P/FCF- EPS past 5Y-63.40% ROI- 52W High-64.38% Beta2.03
Dividend %- Quick Ratio9.60 Sales past 5Y- Gross Margin- 52W Low48.84% ATR0.73
Employees372 Current Ratio9.60 Sales Q/Q- Oper. Margin- RSI (14)63.08 Volatility5.69% 4.59%
OptionableYes Debt/Eq0.00 EPS Q/Q-1.90% Profit Margin- Rel Volume0.60 Prev Close15.99
ShortableYes LT Debt/Eq0.00 EarningsNov 07 BMO Payout- Avg Volume693.50K Price15.45
Recom2.20 SMA209.27% SMA5016.00% SMA200-26.96% Volume417,201 Change-3.38%
Nov-08-19Downgrade JP Morgan Overweight → Neutral $43 → $22
Sep-27-19Downgrade Goldman Neutral → Sell $14 → $9
Sep-16-19Downgrade Jefferies Buy → Hold $32 → $15
Jun-04-19Upgrade Citigroup Sell → Neutral $23 → $24
May-30-19Initiated ROTH Capital Buy
May-23-19Initiated Stifel Buy
Jan-23-19Initiated Mizuho Buy
Apr-10-18Initiated JP Morgan Overweight $56
Mar-16-18Initiated Guggenheim Neutral
Mar-05-18Reiterated Jefferies Buy $30 → $46
Feb-28-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-15-18Downgrade Citigroup Neutral → Sell
Jan-03-18Upgrade Citigroup Sell → Neutral
Oct-06-17Resumed Goldman Neutral
Jun-22-17Resumed Jefferies Buy $30
Oct-24-16Resumed Jefferies Buy
Sep-15-16Downgrade Goldman Neutral → Sell
Dec-15-15Downgrade Citigroup Buy → Sell
Nov-18-15Resumed Goldman Neutral
Sep-25-15Initiated JMP Securities Mkt Perform
Dec-11-19 11:04PM  Hedge Funds Have Never Been More Bullish On Atara Biotherapeutics Inc (ATRA) Insider Monkey +5.51%
Dec-10-19 12:22PM  Seth Klarman Pares Paratek Pharmaceuticals Stake GuruFocus.com
Dec-09-19 10:00AM  Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-26-19 04:00PM  Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference GlobeNewswire
Nov-12-19 09:00AM  Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why Zacks
Nov-08-19 05:02AM  Edited Transcript of ATRA earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-07-19 07:30AM  Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress GlobeNewswire +11.18%
Nov-06-19 09:01AM  Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Oct-30-19 04:05PM  Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019 GlobeNewswire
Oct-28-19 12:39PM  Did Hedge Funds Drop The Ball On Atara Biotherapeutics Inc (ATRA)? Insider Monkey
Oct-25-19 06:11PM  Atara Biotherapeutics Announces Executive Departures GlobeNewswire
Sep-27-19 11:54AM  ATRA Stock Hits Five-Year Low on Goldman Bear Note Schaeffer's Investment Research
10:50AM  Atara Biotherapeutics Stock Falls After Goldman Downgrade Barrons.com
Sep-26-19 07:37AM  Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Invest In Growth? Simply Wall St.
Sep-23-19 01:16PM  Seth Klarman Further Increases Translate Bio Stake GuruFocus.com -5.12%
05:54AM  3 Biotech Stocks Surging on Positive Results TipRanks
Sep-13-19 07:40AM  The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans Benzinga
06:15AM  Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019 GlobeNewswire
Sep-12-19 06:21PM  3 Small-Cap Stock Picks From Seth Klarman GuruFocus.com
Sep-10-19 01:58PM  Baupost's Seth Klarman Dives Further Into Translate Bio GuruFocus.com +5.97%
Sep-09-19 08:00AM  Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019 GlobeNewswire +5.29%
Aug-28-19 04:05PM  Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference GlobeNewswire
10:02AM  Are Options Traders Betting on a Big Move in Atara (ATRA) Stock? Zacks
Aug-16-19 08:35AM  Edited Transcript of ATRA earnings conference call or presentation 8-Aug-19 12:00pm GMT Thomson Reuters StreetEvents +5.32%
Aug-08-19 02:43PM  Atara Biotherapeutics, Inc. (ATRA) Q2 2019 Earnings Call Transcript Motley Fool
07:30AM  Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress GlobeNewswire
Aug-05-19 02:08PM  Analysts Recommend These 2 Falling Knives GuruFocus.com
Aug-01-19 04:00PM  Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019 GlobeNewswire
Jul-18-19 11:52PM  Atara Biotherapeutics Announces Pricing of $150.0 Million Public Offering GlobeNewswire
04:01PM  Atara Biotherapeutics Announces Proposed Offering of Common Stock GlobeNewswire
Jul-16-19 07:00AM  Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year GlobeNewswire -11.94%
Jul-09-19 01:58PM  5 Immunotherapy Stocks to Keep a Close Eye On GuruFocus.com
08:00AM  Why Atara Biotherapeutics Has Slumped in 2019 Motley Fool
Jul-01-19 09:25AM  Atara Reports Initial Data for Multiple Sclerosis Candidate Zacks
Jun-29-19 07:00AM  Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN) GlobeNewswire
Jun-25-19 04:05PM  Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-23-19 03:52PM  Were Hedge Funds Right About Flocking Into Atara Biotherapeutics Inc (ATRA) ? Insider Monkey
Jun-05-19 04:30PM  Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Jun-04-19 09:36AM  Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma GlobeNewswire
Jun-03-19 11:00AM  Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO American City Business Journals
Jun-01-19 09:00AM  Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-30-19 05:38PM  Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences GlobeNewswire
May-28-19 05:00PM  Atara Biotherapeutics Appoints Pascal Touchon President, Chief Executive Officer and Member of the Board of Directors GlobeNewswire
May-24-19 05:24AM  Edited Transcript of ATRA earnings conference call or presentation 9-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-15-19 05:05PM  Atara Biotherapeutics Announces Presentations Highlighting Tab-cel® and Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
08:30AM  Atara Biotherapeutics Announces Presentation of Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN) GlobeNewswire
May-09-19 03:25PM  Why Atara Biotherapeutics Stock Is Imploding Today Motley Fool -20.60%
08:19AM  Atara Biotherapeutics: 1Q Earnings Snapshot Associated Press
08:00AM  Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress GlobeNewswire
06:30AM  Atara Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-07-19 04:41PM  Atara Biotherapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019 GlobeNewswire -7.72%
09:00AM  Where Will Gilead Sciences Spend Its Cash? Motley Fool
May-02-19 12:42PM  Here is What Hedge Funds Think About Atara Biotherapeutics Inc (ATRA) Insider Monkey
Apr-23-19 08:44AM  2 Best Biotech Buyout Plays Motley Fool +5.68%
Apr-01-19 04:10PM  Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Mar-31-19 11:00AM  Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma GlobeNewswire
Mar-08-19 01:55PM  The Atara Biotherapeutics (NASDAQ:ATRA) Share Price Has Gained 122%, So Why Not Pay It Some Attention? Simply Wall St.
Mar-07-19 09:00AM  Atara Biotherapeutics to Participate in Upcoming Conferences GlobeNewswire
Mar-06-19 05:20PM  How attacking a virus in cancer patients helped a Peninsula company target MS American City Business Journals -6.20%
Feb-27-19 05:20PM  Atara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Feb-26-19 07:30AM  Atara Biotherapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress GlobeNewswire -10.73%
Feb-13-19 08:00AM  Consolidated Research: 2019 Summary Expectations for T-Mobile US, WestRock, Shake Shack, Atara Biotherapeutics, CorVel, and Transdigm Group Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-08-19 12:50PM  At biotech's big event, a chance for execs to shape LGBTQ diversity on boards American City Business Journals +5.91%
Jan-04-19 04:05PM  Atara Biotherapeutics to Participate in the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.49%
10:01AM  Company News For Jan 4, 2019 Zacks
Jan-03-19 04:32PM  Why Delta Air Lines, Atara Biotherapeutics, and Skyworks Solutions Slumped Today Motley Fool -19.46%
07:40AM  Atara Biotherapeutics Announces Planned Chief Executive Officer Transition GlobeNewswire
07:30AM  Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy for Solid Tumors GlobeNewswire
Dec-21-18 11:23PM  Should You Avoid Atara Biotherapeutics Inc (ATRA)? Insider Monkey -7.82%
Dec-15-18 08:00AM  Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS) GlobeNewswire
Dec-03-18 08:45PM  Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting GlobeNewswire +6.28%
Nov-29-18 02:50PM  Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline GlobeNewswire
Nov-27-18 08:30AM  Atara Biotherapeutics to Host CAR T Breakfast Teach-In on November 29, 2018 GlobeNewswire
Nov-19-18 08:30AM  Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy GlobeNewswire
Nov-06-18 08:11AM  Atara Biotherapeutics: 3Q Earnings Snapshot Associated Press
07:30AM  Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress GlobeNewswire
Nov-01-18 09:03AM  Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology (ASH) Annual Meeting and European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2018 GlobeNewswire +8.81%
Oct-16-18 07:40AM  Report: Exploring Fundamental Drivers Behind Monroe Capital, Anavex Life Sciences, Haynes International, Atara Biotherapeutics, Lands' End, and Envestnet New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +7.82%
Sep-26-18 08:41AM  Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher Zacks
Sep-24-18 04:55PM  Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-11-18 08:00AM  Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors GlobeNewswire
Sep-06-18 07:30AM  Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies GlobeNewswire
Aug-31-18 08:00AM  Atara Biotherapeutics to Participate at Two Upcoming Conferences GlobeNewswire
Aug-16-18 07:40AM  Analysis: Positioning to Benefit within Quanex Building Products, Molecular Templates, Atara Biotherapeutics, Forward Industries, Apollo Endosurgery, and Myomo Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-06-18 04:50PM  Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-01-18 08:12AM  Atara Biotherapeutics: 2Q Earnings Snapshot Associated Press
08:00AM  Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress GlobeNewswire
Jul-31-18 04:45PM  Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jul-12-18 07:15AM  Free Pre-Market Technical Recap on ArQule and Three Additional Biotech ACCESSWIRE
Jun-25-18 08:00AM  Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline GlobeNewswire
Jun-20-18 11:30AM  2 High-Flying Biotech Stocks With Even More Room to Grow Motley Fool +5.39%
06:01AM  3 Small-Cap Biotech Stocks to Keep on Your Radar Motley Fool
Jun-18-18 09:42AM  Why this Peninsula cell therapy company joined biotech's 'unprecedented' manufacturing boom American City Business Journals
Jun-15-18 02:30AM  Atara Biotherapeutics Tab-cel Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas GlobeNewswire
Jun-13-18 08:00AM  Atara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus (EBV) Infection and Multiple Sclerosis (MS) GlobeNewswire
07:05AM  Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities ACCESSWIRE
Jun-07-18 05:20PM  Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -8.34%
08:00AM  Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer GlobeNewswire
Jun-03-18 09:02AM  3 Top Growth Stocks to Buy Right Now Motley Fool
May-29-18 04:05PM  Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences GlobeNewswire
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Newell JoeChief Tech. Operations OfficerSep 27Sale13.513,50047,28557,998Sep 30 04:25 PM
DOBMEIER ERICDirectorJun 27Buy19.502,00039,00016,000Jul 01 05:01 PM
Ciechanover Isaac E.Chief Executive OfficerMay 30Sale23.222,92567,926290,687May 31 04:16 PM
Ciechanover Isaac E.Chief Executive OfficerMay 29Sale22.962,92567,163293,612May 31 04:16 PM
Ciechanover Isaac E.Chief Executive OfficerMay 14Sale24.923,90097,188296,537May 15 04:35 PM
Ciechanover Isaac E.Chief Executive OfficerMay 13Sale24.303,90094,785300,437May 15 04:35 PM
Newell JoeChief Tech. Operations OfficerMay 06Option Exercise20.401,50030,60062,998May 07 04:31 PM
Newell JoeChief Tech. Operations OfficerMay 06Sale35.001,50052,50061,498May 07 04:31 PM
Ciechanover Isaac E.Chief Executive OfficerApr 26Sale33.473,900130,533304,337Apr 29 05:36 PM
Ciechanover Isaac E.Chief Executive OfficerApr 25Sale33.603,900131,049308,237Apr 29 05:36 PM
Ciechanover Isaac E.Chief Executive OfficerApr 11Sale36.273,900141,453312,137Apr 12 04:19 PM
Ciechanover Isaac E.Chief Executive OfficerApr 10Sale37.043,900144,456316,037Apr 12 04:19 PM
Newell JoeChief Tech. Operations OfficerApr 01Option Exercise20.401,50030,60063,646Apr 03 07:22 PM
Newell JoeChief Tech. Operations OfficerApr 01Sale39.961,50059,94062,146Apr 03 07:22 PM
Ciechanover Isaac E.Chief Executive OfficerMar 29Sale39.913,900155,637319,937Apr 01 04:16 PM
Ciechanover Isaac E.Chief Executive OfficerMar 28Sale37.413,900145,909323,837Apr 01 04:16 PM
MARCUS JOEL SDirectorMar 15Sale38.2520,000765,000888,355Mar 19 04:19 PM
Ciechanover Isaac E.Chief Executive OfficerMar 15Sale38.733,900151,047327,737Mar 18 04:13 PM
Ciechanover Isaac E.Chief Executive OfficerMar 14Sale40.233,900156,906331,637Mar 18 04:13 PM
Newell JoeChief Tech. Operations OfficerMar 01Option Exercise20.401,50030,60048,646Mar 05 06:58 PM
Newell JoeChief Tech. Operations OfficerMar 01Sale36.131,50054,20247,146Mar 05 06:58 PM
MARCUS JOEL SDirectorFeb 28Sale36.0762,5902,257,6217,500Mar 01 04:09 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 28Sale36.133,900140,907335,537Mar 01 04:10 PM
MARCUS JOEL SDirectorFeb 27Option Exercise19.9762,5001,248,01570,090Mar 01 04:09 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 27Sale36.153,900140,984339,437Mar 01 04:10 PM
Porter DerrellSVP, Head of Global CommercialFeb 15Option Exercise14.304,00057,20027,597Feb 19 05:05 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfFeb 15Sale39.5977530,682271,943Feb 19 05:08 PM
Porter DerrellSVP, Head of Global CommercialFeb 15Sale40.005,909236,36021,688Feb 19 05:05 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 12Sale39.013,900152,139342,138Feb 12 07:18 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 11Sale38.523,900150,228346,038Feb 12 07:18 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfFeb 11Sale38.5513,975538,736272,718Feb 11 07:10 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfFeb 06Sale38.6212,375477,922273,205Feb 08 04:28 PM
Newell JoeChief Tech. Operations OfficerFeb 02Sale38.4450019,22031,858Feb 01 06:49 PM
Newell JoeChief Tech. Operations OfficerFeb 01Option Exercise20.401,50030,60033,358Feb 01 06:49 PM
Newell JoeChief Tech. Operations OfficerFeb 01Sale37.801,00037,80032,358Feb 01 06:49 PM
Ciechanover Isaac E.Chief Executive OfficerJan 24Sale35.073,900136,783296,452Jan 25 08:16 PM
Ciechanover Isaac E.Chief Executive OfficerJan 23Sale35.043,900136,650300,352Jan 25 08:16 PM
Ciechanover Isaac E.Chief Executive OfficerJan 10Sale34.253,900133,5814,078Jan 10 06:08 PM
Ciechanover Isaac E.Chief Executive OfficerJan 09Sale34.843,900135,8897,978Jan 10 06:08 PM
Newell JoeChief Tech. Operations OfficerJan 02Option Exercise20.401,50030,60033,358Jan 02 07:51 PM
Newell JoeChief Tech. Operations OfficerJan 02Sale35.001,50052,50031,858Jan 02 07:51 PM
Ciechanover Isaac E.Chief Executive OfficerDec 28Sale34.703,900135,34011,878Dec 28 06:51 PM
Ciechanover Isaac E.Chief Executive OfficerDec 27Sale33.053,900128,89315,778Dec 28 06:51 PM
open in yahoo | open in reuters | open in google